What's Going On With Silence Therapeutics Stock Today?
What's Going On With Silence Therapeutics Stock Today?
Silence Therapeutics Plc (NASDAQ:SLN) shares are trading lower in the morning session on Wednesday.
Silence Therapeutics Plc（纳斯达克股票代码：SLN）股价在周三上午的交易中走低。
The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago. Collaboration revenues were £25.4 million versus £17.501 million a year ago.
该公司报告称，2023年每股亏损为（38.9）便士，低于去年同期的每股亏损（41.9）便士。合作收入为2540万英镑，去年同期为17501万英镑。
Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022.
2023年的净亏损为4,330万英镑，而2022年的净亏损为4,050万英镑。
"We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million," said Rhonda Hellums, Chief Financial Officer of Silence.
Silence首席财务官朗达·海勒姆斯表示：“截至2023年12月，我们的现金状况约为6,880万美元，并在2024年初大幅增加到2亿美元以上。”
In March 2024, Mallinckrodt (OTC:MNKTQ) notified Silence that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial. This will conclude all activities and commitments under the collaboration agreement.
2024 年 3 月，Mallinckrodt（场外交易代码：MNKTQ）通知 Silence，在 1 期临床试验完成后，他们不会继续进一步开发 SLN501。这将结束合作协议下的所有活动和承诺。
Silence also announced topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran in patients with a median baseline Lp(a) of approximately 215 nmol/L.
Silence还公布了正在进行的针对zerlasiran的 ALPACAR-360 2期研究的36周主要数据，该研究针对中位基线Lp（a）约为215 nmol/L的患者。
Zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks. The company said the study demonstrated highly significant reductions in Lp(a) compared with placebo to week 36 (primary endpoint).
Zerlasiran 每 16 或 24 周皮下给药 300 mg，每 24 周给药 450 mg。该公司表示，该研究表明，与安慰剂相比，Lp（a）至第36周（主要终点）显著降低。
"We are excited to have multiple programs advancing in the clinic, supported by a substantial cash position that extends our estimated runway into 2026," Hellums added.
Hellums补充说：“我们很高兴在大量现金状况的支持下，临床上有多个项目正在取得进展，这使我们的预计投资期延长至2026年。”
Last month, Silence Therapeutics said that the initiation by AstraZeneca PLC (NASDAQ:AZN) of phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration had triggered a $10.0 million milestone payment to the firm.
上个月，Silence Therapeutics表示，阿斯利康公司（纳斯达克股票代码：AZN）启动了对siRNA（短干扰RNA）合作下的首个候选产品的1期临床试验，这引发了向该公司支付的1,000万美元的里程碑式付款。
Price Action: SLN shares are trading lower by 5.61% to $24.45 on the last check Wednesday.
价格走势：在周三的最后一次支票中，SLN股价下跌5.61％，至24.45美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 创作的 Phrama 实验室工作人员的插图。